Subclinical thyroid disorders are commonly encountered in the primary care setting. This article aims to review the latest evidence and guidelines pertaining to the management of subclinical hypo-and hyperthyroidism, in particular the important decision of when treatment should be considered.
INTRODUCTION
Subclinical thyroid disorders are not uncommon in primary care. Many patients with subclinical thyroid disorders are discovered incidentally during health screening conducted by family physicians. Stable patients followed up by restructured hospitals often undergo transition of care to the family physician for long-term management. These examples highlight some of the ways in which family physicians may find themselves managing subclinical thyroid disorders.
This article aims to review the latest evidence and recommendations for the management of subclinical thyroid disorders, including the important decision of treatment initiation from the perspective of a family physician.
SUBCLINICAL HYPOTHYROIDISM
Subclinical hypothyroidism is defined biochemically as "a serum thyroid stimulating hormone (TSH) level above the upper reference limit in combination with a normal free thyroxine level, provided that the thyroid function has been stable for weeks, the hypothalamic-pituitarythyroid axis is normal, and there is absence of recent or ongoing severe illness" 1 . Some patients with subclinical hypothyroidism may have symptoms suggestive of hypothyroidism but symptoms are non-specific and may be present in euthyroid persons 2 . Most guidelines recommend rechecking serum TSH within 3-6 months to confirm persistence of elevated TSH 3, 4 .
Differential diagnosis of raised serum TSH
Before making a diagnosis of subclinical hypothyroidism, other conditions that cause serum TSH to be raised should be excluded. Thyroid stimulating hormone levels may be raised as a result of acute nonthyroidal illness 5 . Patients with nonfunctioning pituitary adenomas, with central hypothyroidism, may have mildly elevated serum TSH levels due to secretion of TSH, which has reduced biologic activity 6, 7 . In central hypothyroidism, serum free T4 is usually low, differentiating it from subclinical primary hypothyroidism. Adrenal insufficiency may be associated with TSH elevations that are reversed with glucocorticoid replacement 8, 9 .
Aetiology of subclinical hypothyroidism
The same conditions that cause overt hypothyroidism can cause subclinical hypothyroidism 10, 11 and the most common cause is chronic autoimmune (Hashimoto's) thyroiditis [11] [12] [13] . Other causes include inadequate replacement therapy for overt hypothyroidism, drugs impairing thyroid function (e.g. amiodarone, lithium), subacute, postpartum and painless thyroiditis, thyroid injury (from partial thyroidectomy, radioactive iodine therapy, external Proceedings of Singapore Healthcare  Volume 23  Number 3  2014 of hypothyroidism (for example, higher likelihood of progression seen post-radioiodine therapy and underlying autoimmune thyroid disease 25 ) and the age of the patient (risk of progression appears to be less common in children and adolescents 26, 27 ). More-over subclinical hypothyroidism may be a transient disease with spontaneous normalisation of TSH levels 23, 24, 28, 29 . Recovery of thyroid function is more likely if basal TSH levels were below 10 mIU/L, coupled with the absence of antithyroid peroxidase antibodies 21 .
Cardiovascular events and mortality
Cohort studies have reported conflicting results, with some studies finding no association between subclinical hypothyroidism and cardiovascular events/mortality [30] [31] [32] [33] , and many others finding a positive association between the two 34-41 .
Rodondi et al. established the Thyroid Studies
Collaboration to collect 55,287 individual participant data from 11 international prospective cohorts, and suggested that subclinical hypothyroidism was associated with an increased risk of CHD events and mortality in those with higher TSH levels, particularly when TSH >10 mIU/L 38 . Risks did not significantly differ according to the age of the patient, even though a number of other studies 30, 34, 36, 42 suggest that the negative effects of subclinical hypothyroidism on cardiovascular risk may be less evident in older patients. A meta-analysis by Razvi et al. 35 also suggested that the risk of ischaemic heart disease and cardiovascular mortality is higher in patients who are younger than age 65 years. The effects of subclinical hypothyroidism in the elderly is discussed further under the section on 'Special populations groups affecting treatment considerations: elderly' .
Patients with subclinical hypothyroidism were also found to have other markers of increased cardiovascular risk such as raised C-Reactive Protein, increased arterial stiffness, endothelial dysfunction and increased carotid intima thickness [43] [44] [45] [46] . With regard to cardiovascular risk factors, a recent meta-analysis 47 of cross sectional data suggested association between subclinical hypothyroidism and systolic hypertension. Available data linking subclinical hypothyroidism to hyperlipidemia is conflicting. Some studies 43, 44, [48] [49] [50] [51] show an association with subclinical hypothyroidism while others 15, 20, 52 show no correlation. Thus based on data, subclinical hypothyroidism may potentially increase the risk of atherosclerosis and coronary artery disease. head and neck radiotherapy, infiltrative diseases), and toxic substances 14 .
Prevalence of subclinical hypothyroidism
Using an upper limit of normal for TSH as 4.5 mIU/L, the National Health and Nutrition Examination Survey (NHANES III) of an unselected U.S population found subclinical hypothyroidism in 4.3% of the reference population 15 . A local prospective observational study in a restructured hospital found subclinical hypothyroidism in 2.2% of admitted geriatric patients 16 . There is debate on what the upper limit of normal for TSH should be [17] [18] [19] . Higher rate of progression to overt disease 17, 20 as well as higher levels of antithyroid antibodies 17 found in persons with TSH at the upper range of normal support lowering of the upper limit to narrow the range of normal for TSH, whereas spontaneous normalisation occurring in some patients with mildly elevated TSH 21 and the possibility of over treatment leading to iatrogenic hyperthyroidism with its antecedent ill effects argues against lowering the upper limit. As such, the true prevalence of subclinical hypothyroidism is somewhat uncertain because of the inability to specify the normal range of TSH.
Consequences of subclinical hypothyroidism
The clinical risks associated with subclinical hypothyroidism have been extensively studied, with particular focus on the risk of progression to overt hypothyroidism (i.e. the natural history of subclinical hypothyroidism), its effect on the cardiovascular system, namely coronary heart disease (CHD) and mortality as well as heart failure.
Progression to overt hypothyroidism (natural history of subclinical hypothyroidism)
Some patients with subclinical hypothyroidism progress to overt disease while in some patients, thyroid function may normalise. Several factors influence progression to overt disease. Progression to overt disease is more likely with higher degree of TSH elevation and the presence of antithyroid peroxidase antibodies 20, [22] [23] [24] . A twenty-year follow up in the Whickham Study 20 had shown that in the presence of antithyroid peroxidase antibodies, the annual rate of progression to overt hypothyroidism was 4·3% compared to 2·6% if thyroid antibodies were negative.
Other factors affecting risk of progression to overt hypothyroidism include the underlying aetiology Heart failure Two cohort studies have assessed the relation between subclinical hypothyroidism and heart failure in elderly patients. The first study 33 looked at subjects aged 70 years and above and found the risk of heart failure to be increased with TSH level of 7.0 mIU/L or greater. The risk of heart failure was greater with higher levels of TSH (relative risk of 2.6 with TSH 7·0-9·9 mIU/L and 3·26 for those with serum TSH of 10 mIU/L or greater). The other study 53 looked at subjects aged 65 years and above and noted increased heart failure risk only in those with a TSH concentration of 10 mIU/L or greater. In this same study 53 , patients with subclinical hypothyroidism who were treated with levothyroxine had significantly lower risk of heart failure events.
A review by Biondi and Cooper 14 noted consistent association between subclinical hypothyroidism and left ventricular diastolic dysfunction while the association with systolic dysfunction is less consistent. Resting and exercise doppler echocardiography and radionuclide studies showed slowed ventricular relaxation and impaired ventricular filling indicating diastolic dysfunction in subclinical hypothyroid patients compared to euthyroid subjects.
Finally, Gencer et al. 54 performed a pooled analysis of 25,390 individual participant data from six prospective cohorts in the United States and Europe and found an increased risk of heart failure events when TSH >10 mIU/L.
Others
The effect of subclinical hypothyroidism on cognitive and neuropsychological function yielded conflicting results from studies. One study showed no cognitive and neuropsychological dysfunction in subjects with subclinical hypothyroidism when compared to healthy controls, while another found cognitive impairment in subjects with subclinical hypothyroidism which normalised after thyroxine replacement 55 .
Special population groups affecting treatment considerations Pregnant women
Physiological changes during pregnancy can be reflected in thyroid function tests 56, 57 . For example, increased thyroid binding globulin (TBG) during pregnancy increases serum total T4 and T3 compared to non-pregnant states, while first trimester human chorionic gonadotrophin (hCG) increases serum free T4 with appropriate suppression of TSH 58 . Changes in thyroid physiology probably relate to the need for maternal free T4 to be delivered to foetus in the first trimester for neural development 57 . It is clear that trimester-specific ranges are required for correct diagnosis of thyroid disease in pregnancy. Guidelines cosponsored by the American Thyroid Association and the American Association of Clinical Endocrinologists (ATA/AACE) 1 had recommended using trimesterspecific upper limit of normal reference ranges for TSH, if available at the particular laboratory. If trimester-specific ranges are unavailable for the particular laboratory, upper-normal reference ranges of 2.5 mIU/L, 3 mIU/L and 3.5 mIU/L are recommended for the first, second and third trimester respectively. The Endocrine Society (JCEM 2012) 59 also suggested trimester-specific TSH ranges if available at the particular laboratory. If trimester-specific ranges are unavailable, they suggest an upper normal limit of 2.5 mIU/L for the first trimester and 3 mIU/L for both the second and third trimesters.
Subclinical
hypothyroidism in pregnancy is associated with poor obstetric outcomes including stillbirths, abruptio placentae, preeclampsia and preterm delivery with resultant low birth weight [60] [61] [62] . One study 63 suggested developmental delay in infants born to mothers with subclinical hypothyroidism.
While a Cochrane review published in 2013 on interventions for hypothyroidism pre-and during pregnancy found insufficient evidence to recommend the use of intervention with thyroxine for improving outcome, it is worth noting that the review only included four trials of moderate risk of bias and involved mainly hypothyroid subjects or those with positive thyroid antibodies 64 .
In contrast, the ATA/AACE guidelines 1 specifically mention pregnancy as a possible consideration for treating patients with subclinical hypothyroidism. The guidelines recommend thyroxine therapy if TSH is greater than 2.5 mIU/L and the patient has or previously had positive anti-thyroid peroxidase antibodies.
Independent of anti-thyroid peroxidase status, treatment should also be considered if serum TSH
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Due to the complexity of management and possibility of adverse foetal outcomes, our advice for family physicians is to co-manage a pregnant patient with subclinical hypothyroidism with the obstetrician and endocrinologist.
The elderly
It has been known that elevated TSH levels occur with increasing frequency with aging, with 40% and 14.5% of elderly individuals in one study 65 having TSH levels >2.5 and 4.5 mIU/L respectively.
The effect of subclinical hypothyroidism on the elderly has generated conflicting results. Rodondi et al. 39 had found that subclinical hypothyroidism increased risk of CHD events and mortality particularly when TSH >10 mIU/L, even in the elderly while several studies 30, [34] [35] [36] [37] had noted that the risk of cardiovascular disease (CVD) and mortality was not seen in the elderly as compared to the younger population.
Rodondi et al.'s findings 38 of increased cardiovascular risk in the elderly have been called into question by two recent studies published in 2013. In the Cardiovascular Health Study 42 , Hyland et al. noted that elderly patients aged 65 years and above with subclinical hypothyroidism did not have increased risk of coronary heart disease, heart failure or cardiovascular deaths regardless of serum TSH levels. The investigators also did not find any subset of older adults to target for therapy, and concluded that their findings did not support the treatment of subclinical hypothyroidism in this group. It has previously been shown that treatment with L-thyroxine did not confer any benefits in the elderly, even though treatment of younger patients with subclinical hypothyroidism was associated with fewer cardiovascular events 37 .
A review by Pasqualetti et al. covered existing literature and affirmed that while the negative effects of subclinical hypothyroidism on cardiovascular events and mortality are well established in adults ≤60 years old, the effect is less evident in the moderately old (<70-75 years old) and may be absent in those aged >80 years 66 . However as quoted by the authors, one study 67 reported increased risk of heart failure in subjects aged 70-82 years with known cardiovascular risk factors or pre-existing cardiovascular disease when TSH was persistently elevated. The authors concluded that any decision to treat elderly patients with subclinical hypothyroidism should take into account factors which include level of serum TSH and pre-existing cardiovascular risk.
In the Leiden study 68 of subjects aged 85 years and older, abnormally high levels of TSH was not associated with functional disability, depressive symptoms nor cognitive impairment but was instead associated with a lower mortality rate. These findings suggest that raised TSH in the elderly may be as a result of age-related physiological change in set-point 69 .
When should we treat?
Most authors as well as the ATA/AACE guidelines 1 recommend treatment with thyroxine for individuals with subclinical hypothyroidism and TSH >10 mIU/L; opinions differ in management when TSH ranges between 4.5 and 10 mIU/L, with some authors recommending routine treatment 70, 71 and others against 3 . 14 had proposed that the decision to treat or not to treat subclinical hypothyroidism when serum TSH is above the upper reference range yet below 10 mIU/L should be based on consideration of whether symptoms are present, the underlying aetiology of hypothyroidism (e.g. whether there was evidence of autoimmune thyroiditis such as positive anti-thyroid peroxidase antibodies), presence of atherosclerotic disease or risk factors or heart failure. This is consistent with the ATA/AACE guidelines 1 . For patients with TSH <10 mIU/L for whom the decision is not for treatment, clinical assessment and monitoring of TSH levels can be performed every 6-12 months 3 . Up to 60% of subclinically hypothyroid patients with TSH <10 mIU/L may revert to normal with repeat testing of serum TSH 29 . An approach to the diagnosis and treatment of subclinical hypothyroidism is presented in Fig. 1 .
Biondi and Cooper

How do we treat?
The ATA/AACE guidelines approximate the daily thyroxine requirement of patients with low levels of functional thyroid reserve at 1.6 μg/kg body weight 72, 73 . Most patients with subclinical hypothyroidism require smaller dosages to achieve Proceedings of Singapore Healthcare  Volume 23  Number 3  2014 euthyroidism [74] [75] [76] [77] , with 25-75 μg being sufficient for most 75 , except those with higher TSH levels 76 .
One study used the initial TSH level to determine the starting dose of thyroxine: 25 μg for TSH 4-8 mIU/L, 50 μg for TSH 8-12 mIU/L, 75 μg for TSH >12 mIU/L. With the above dosing, euthyroidism was achieved with few adjustments after two months 77 . For elderly patients and those with pre-existing cardiac disease, lower starting doses of thyroxine with a slower rate of dose increase is recommended.
The path forward
While there is a better understanding of the management of subclinical hypothyroidism, many clinical uncertainties still remain and research findings to answer key questions are often conflicting. Most of the current evidence is derived from cohort studies and there is a lack of randomised clinical trials on important clinical outcomes. 78 that additional observational data is unlikely to adequately address the uncertainties regarding the risks of subclinical hypothyroidism and the benefits/harm of therapy. The authors suggested that these concerns would be best addressed with appropriate randomised controlled trials.
Rodondi et al. commented in an editorial
One such study is currently underway -the Thyroid Hormone Replacement for Subclinical Hypothyroidism (TRUST) study is a multi-centre randomised-placebo controlled trial to assess the impact of thyroxine replacement in 3,000 older adults with persistent subclinical hypothyroidism 79 .
SUBCLINICAL HYPERTHYROIDISM Definition
Subclinical hyperthyroidism is characterised by a serum TSH level below the lower reference limit in combination with a normal free thyroxine level 3 . The definition only applies if the thyroid function has been stable for weeks, the hypothalamic-pituitarythyroid axis is normal, and there is absence of recent or ongoing severe illness 4 . Patients with subclinical hyperthyroidism may have typical symptoms of thyroid hormone excess such as palpitations, tremor, heat intolerance, sweating, anxiety, reduced feeling of well-being, hostility, and inability to concentrate 80 .
Differential diagnosis of suppressed serum TSH
Before making a diagnosis of subclinical hyperthyroidism, it is important to consider some conditions that may result in TSH suppression. The differential diagnosis of low serum TSH includes transient suppression during subacute, silent or post-partum thyroiditis, non-thyroidal illness, psychiatric illness, central hypothyroidism, TSH suppression by drugs such as corticosteroids or age-related decreased thyroid hormone clearance or altered hypothalamic-pituitary-thyroid axis setpoint 14, [80] [81] [82] . While these conditions may cause a similar looking biochemical picture, they are not causes of subclinical hyperthyroidism.
Aetiology of subclinical hyperthyroidism
The most common cause of subclinical hyperthyroidism is exogeneous ingestion of L-thyroxine, for example as occurs in overreplacement for hypothyroidism or intentional TSH suppressive therapy for a variety of thyroid diseases 2,14,83-87 . Endogeneous subclinical hyperthyroidism, which occurs in the absence of thyroxine intake, reflects autonomous thyroid function and is commonly due to Graves' Diseases, multinodular goitre or solitary toxic nodules 10, 14 . In older persons, toxic multinodular goitre is probably the most common cause 23 . Determining the underlying aetiology of subclinical hyperthyroidism is important as it has some bearing on the natural history. This is further discussed later.
Prevalence of subclinical hyperthyroidism
The prevalence of subclinical hyperthyroidism, taking into account endogeneous and exogeneous causes varies between 0.7 and 12.4% 88 . This variability is partly due to differences in investigators' definitions of the lower limit of normal for TSH 14 . Endogeneous subclinical hyperthyroidism is more prevalent in the elderly and in females 2, 51, [89] [90] [91] [92] [93] .
Consequences of subclinical hyperthyroidism
Decreased serum TSH has been associated with progression to overt hyperthyroidism, atrial fibrillation, reduced bone mineral density, and cardiac dysfunction 94, 95 .
Progression to overt hyperthyroidism (natural history of subclinical hyperthyroidism)
The frequency with which subclinical hyperthyroidism progresses to overt disease depends upon degree of TSH suppression as well as the underlying aetiology.
Data has suggested that the course of subclinical hyperthyroidism due to Graves' disease is more variable, with higher chance of spontaneous remission as compared to persisting unchanged in multinodular goitre, while patients with solitary autonomous nodules are more likely to progress to overt disease 96 . Patients with low but still detectable (0.1-0.4 mIU/L) serum TSH appeared less likely to progress to overt diseases compared to patients with undetectable (<0.1mIU/L) serum TSH 89 .
Cardiovascular effects
A meta-analysis 97 of cohort studies demonstrated association between subclinical hyperthyroidism and significantly increased cardiovascular risk for the general population and increased all-cause mortality for individuals with comorbidities.
When TSH was iatrogenically suppressed by exogeneous L-thyroxine, there was increased Review Proceedings of Singapore Healthcare  Volume 23  Number 3  2014 comparison to control 119 . The other meta-analysis studied 1,250 subjects enrolled in 41 studies and noted significant bone loss in the lumbar spine and femoral region in post-menopausal women 118 .
Calcium supplementation has been shown to be protective against bone loss in post-menopausal women on suppressive L-thyroxine therapy. Addition of intranasal calcitonin did not appear to improve bone density as compared to calcium alone 120 . Exogeneous subclinical hyperthyroidism was not shown to affect bone metabolism in men [121] [122] [123] . Some, but not all, studies show an increased fracture risk in patients with exogenous subclinical hyperthyroidism from thyroxine therapy [124] [125] [126] . Fracture risk appears to be related to older age and degree of TSH suppression. If TSH levels remain within the normal range, thyroxine therapy itself was not associated with the increased risk of fractures 124 .
As for endogeneous subclinical hyperthyroidism, a few studies have shown adverse effects on bone density in post-menopausal women 116, 127, 128 . Two prospective studies 127, 128 showed improvement in bone mineral densitometry following treatment of post-menopausal women with endogenous subclinical hyperthyroidism.
Pre-menopausal patients with Graves' Disease on maintenance anti-thyroid drug treatment whose TSH remained suppressed had higher levels of serum and urinary bone turnover markers compared to those in whom TSH levels had normalised 129 . One study 130 demonstrated an increased fracture risk in older men, but not women, with endogenous subclinical hyperthyroidism, while another 131 failed to associate an increased risk of fractures with elderly persons of either sex. In a small prospective study 132 , there was no obvious improvement in bone mineral densitometry after six months of treatment with antithyroid drugs in premenopausal women with endogenous subclinical hyperthyroidism. No prospective data are available for fracture risk in treated versus untreated women 4 .
The major difficulty in assessing the effects on bone loss stems from smaller numbers of patients with endogeneous subclinical hyperthyroidism, fewer studies compared to those on exogeneous subclinical hyperthyroidism and difficulty ascertaining duration of underlying disease 14 . Adverse bone effects appear to be related to duration of disease as well as concomitant risk factors for osteoporosis 80 . cardiovascular risk, particularly if TSH is suppressed to undetectable levels 14 . Iatrogenic TSH suppression has been associated with significantly increased left ventricular mass [98] [99] [100] [101] , raised heart rate 98, 99, 102 , raised systolic blood pressure 99 and reduced exercise capacity [103] [104] [105] .
Similarly, subclinical hyperthyroidism due to endogeneous causes had cardiovascular effects with data showing associated increased heart rate [106] [107] [108] , increase in atrial arrhythmias 106, 107 and increased left ventricular mass 106, 107, 109 .
The frequency of atrial fibrillation is increased in patients with subclinical hyperthyroidism. A metaanalysis by Collet et al. 110 pooled individual data from five prospective cohort studies and found that subclinical hyperthyroidism is associated with an increased risk of atrial fibrillation (hazard ratio of 1.68, confidence interval of 1.16-2.43). The risk of atrial fibrillation was even higher if TSH levels were less than 0.10 mIU/L (hazard ratio 2.54) compared with 0.1 to 0.44 mIU/L (hazard ratio 1.63). Even within the normal range, there was association between atrial fibrillation and TSH levels with individuals having TSH levels in the lower quartile having a higher risk of atrial fibrillation compared to those in the highest quartile 111 . Higher risk of atrial fibrillation with subclinical hyperthyroidism is particularly evident in elderly persons 30, [112] [113] [114] .
All-cause mortality, especially that due to cardiovascular disease was also increased in the elderly population 115 . This supports treatment of subclinical hyperthyroidism in the elderly age group.
Bone metabolism
While some studies showed no relation between subclinical hyperthyroidism and increased bone turnover rate 116, 117 , these studies are small and not double blinded with results consistently seen only in pre-menopausal women.
Two meta-analyses 118, 119 assessed the effect of exogeneous subclinical hyperthyroidism and concluded that suppressed TSH levels induced by L-thyroxine therapy increased the risk of bone loss in postmenopausal women. Both studies did not show TSH suppressive therapy to adversely affect bone mineral densitometry in pre-menopausal women. One meta-analysis found that postmenopausal women had significant excess of annual bone loss of 0.91% per year after 9.9 years in Proceedings of Singapore Healthcare  Volume 23  Number 3  2014
Cognitive impairment
With regard to cognitive impairment and dementia, data is conflicting. Some authors suggest subclinical hyperthyroidism may be associated with dementia. In a study involving 1843 participants aged 55 years and older followed up for an average of two years, it was found that those with reduced TSH levels at baseline had a more than three-fold increased risk of dementia and of Alzheimer's disease, especially so in those positive for anti-thyroid peroxidase antibodies 133 , suggesting possible role of autoimmunity. Another two smaller studies correlating dementia patients and their TSH levels found a positive association between dementia (especially vascular dementia) and depressed TSH levels 134, 135 . However, two cross sectional studies of older patients failed to demonstrate an association with cognitive impairment nor depression and anxiety 136, 137 . Thus it is difficult to draw a firm conclusion on the illeffects of subclinical hyperthyroidism on cognitive function and further studies are needed.
Special population groups affecting treatment considerations Pregnant women
The diagnosis of true subclinical hyperthyroidism during pregnancy may be difficult. As mentioned above, physiological changes of normal pregnancy may alter thyroid function tests 56 . In the first trimester, there is a transient rise in free T4 and T3 due to weak thyroid-stimulating activity 138 of peak levels of circulating hCG. The first-trimester rise in free T4 and T3 is usually within the normal range, although this is sometimes exceeded. This rise leads to concomitant TSH suppression, sometimes to low or undetectable levels 56, 139, 140 leading to a biochemical picture which may be mistaken for subclinical hyperthyroidism. Women with hyperemesis gravidarum may have higher degrees of TSH suppression due to higher levels of circulating hCG 140 with higher thyrotropic activity [141] [142] [143] . Biochemical changes in thyroid function due to physiological changes of pregnancy do not require therapy 144 .
Graves Disease is the most common cause of hyperthyroidism during pregnancy 145 . Thyrotropin receptor antibody (TRAb) levels should be measured when the etiology of hyperthyroidism in pregnancy is uncertain 144 . As maternal TRAb can cross the placenta and affect foetal thyroid function, if TRAb is raised (particularly in gestational weeks [22] [23] [24] [25] [26] the pregnancy should be monitored for evidence of foetal thyroid dysfunction 59, 144 .
A study involving 25,765 women undergoing prenatal thyroid screening found a prevalence of subclinical hyperthyroidism of 1.7%. Gestation in this group was less likely to be complicated by gestational hypertension. There was also no significant difference for other adverse pregnancy and neonatal outcomes. Treatment of women with subclinical hyperthyroidism during pregnancy was not recommended based on the above findings 146 . This is in line with recommendations of the Endocrine Society 59 , which concluded there was no evidence that treatment improves pregnancy outcome.
When should we treat?
No consensus exists with regard to the treatment of subclinical hyperthyroidism with recommendations being based on expert opinion. Decision to treat and management strategies would take into account factors such as underlying aetiology, severity of disease (viz. degree of TSH suppression), presence of symptoms and the patient's risk factors (such as age, cardiovascular risk, osteoporotic risk) 14, 144, 147 .
The ATA/AACE guidelines state that for TSH levels persistently below 0.1 mIU/L, treatment should be strongly considered in the following: symptomatic individuals, individuals above 65 years of age, postmenopausal women who are not on estrogens or bisphosphonates; patients with cardiac risk factors, heart disease or osteoporosis 144 . This is confirmed by other authors 13, 94, 95, 112 as the main aim in treatment is to prevent the onset of associated complications, in particular atrial fibrillation, osteopenia and osteoporosis.
When TSH is persistently below the lower limit of normal but above 0.1 mIU/L, treatment of subclinical hyperthyroidism should be considered in the following: symptomatic individuals, individuals above 65 years of age, patients with cardiac disease 144 . The principal benefit of treatment in this population group is to prevent atrial fibrillation.
The decision to treat should always be considered against the possible side effects from treatment. Incidence of radioactive iodine-induced hypothyroidism is 3-6% yearly and patients generally have to be followed up lifelong 148, 149 .
Review
Proceedings of Singapore Healthcare  Volume 23  Number 3  2014 Anti-thyroid therapy may be complicated by 5-10% incidence of allergic dermatitis and serious drug reactions (such as agranulocytosis and drug-induced hepatitis). The latter may occur in approximately 0.3-0.5% of patients 13 . We present our recommended approach for subclinical hyperthyroidism in Fig. 2 .
How do we treat?
Available treatment modalities are the same as that for overt hyperthyroidism: anti-thyroid medications, radioactive iodine (RAI) and surgery.
The ATA/AACE guidelines recommend that the treatment of subclinical hyperthyroidism be based on its etiology. RAI therapy is appropriate in the elderly as toxic multinodular goitre is the most common cause 144 . A study using impedance cardiography in women with endogenous subclinical hyperthyroidism undergoing RAI has also noted success 150 .
Anti-thyroid therapy has also been found to be effective: improvements in various cardiac parameters have been reported in patients with endogenous subclinical hyperthyroidism after restoration of euthyroidism with methimazole 106 . One study involving elderly patients with subclinical hyperthyroidism and atrial fibrillation found anti-thyroid therapy to be beneficial in restoring a normal sinus rhythm 102 .
Treatment with beta-blockers alone may be sufficient to control the cardiovascular-related morbidity from subclinical hyperthyroidism, especially that from atrial fibrillation 39 . In patients with exogenous subclinical hyperthyroidism, the addition of the cardio-selective betablocker bisoprolol to thyroxine therapy for six months significantly reduced the occurrence of supraventricular arrhythmias with improvement of diastolic function 151 .
The path forward
There are at least two ongoing randomised controlled trials regarding treatment of subclinical hyperthyroidism. One of the trials 152 aims to provide evidence that restoration of euthyroidism (normal TSH) improves thyrotoxic symptoms and signs as well as the quality of life, at the same time lowering the risk of subsequent atrial fibrillation and bone loss in subjects with endogenous subclinical hyperthyroidism. Another randomised controlled trial from the UK compares RAI versus usual care in the elderly 153 .
